SKYSONA
Drug
bluebird bio, Inc.
Total Payments
$3.1M
Transactions
90
Doctors
22
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2024 | $737,386 | 28 | 2 |
| 2023 | $2.3M | 62 | 20 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $2.9M | 45 | 94.2% |
| Consulting Fee | $132,016 | 35 | 4.3% |
| Royalty or License | $38,481 | 5 | 1.3% |
| Grant | $5,000 | 1 | 0.2% |
| Space rental or facility fees (teaching hospital only) | $1,000 | 1 | 0.0% |
| Food and Beverage | $198.36 | 3 | 0.0% |
Payments by Type
Research
$2.9M
45 transactions
General
$176,696
45 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| A Phase 3 Study of Lenti-D Drug Product After Myeloablative Conditioning Using Busulfan and Fludarabine in Subjects < 17 Years of Age With Cerebral Adrenoleukodystrophy (CALD) | bluebird bio, Inc. | $2.1M | 0 |
| Longterm Follow-Up of Subjects With Cerebral Adrenoleukodystrophy Who Were Treated With Lenti-D Drug Product | bluebird bio, Inc. | $795,572 | 0 |
| A Postmarketing, Prospective, Multicenter, Observational, Long-Term Safety and Effectiveness Registry Study of Patients with Cerebral Adrenoleukodystrophy (CALD) Treated with Elivaldogene Autotemcel (Stargazer) | bluebird bio, Inc. | $3,190 | 0 |
Top Doctors Receiving Payments for SKYSONA
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Boston, MA | $2.9M | 52 |
| , MD | Hematology & Oncology | Farmington, CT | $28,560 | 4 |
| , M.D | Pediatric Hematology-Oncology | Boston, MA | $20,130 | 3 |
| , M.D | Pediatrics | Memphis, TN | $10,290 | 1 |
| , MD | Pediatric Hematology-Oncology | Birmingham, AL | $8,840 | 2 |
| , MD | Pediatrics | Saint Louis, MO | $8,080 | 1 |
| , MD | Pediatric Hematology-Oncology | Atlanta, GA | $7,625 | 1 |
| , M.D., PH.D | Hematology | Philadelphia, PA | $6,860 | 1 |
| , M.D | Hematology | Houston, TX | $6,860 | 1 |
| , MD | Medical Oncology | New York, NY | $6,766 | 7 |
| , MD | Pediatric Hematology-Oncology | Bronx, NY | $6,660 | 1 |
| , MD | Internal Medicine | Durham, NC | $4,050 | 2 |
| John Zaia | — | Duarte, CA | $3,300 | 1 |
| , MD | Pediatric Hematology-Oncology | Chicago, IL | $2,800 | 3 |
| , MD | Pediatric Hematology-Oncology | Boston, MA | $2,720 | 1 |
| , MD | Pediatric Cardiology | Los Angeles, CA | $2,550 | 1 |
| , MD | Pediatric Hematology-Oncology | Philadelphia, PA | $2,380 | 2 |
| , MD | Pediatric Hematology-Oncology | Chicago, IL | $1,420 | 1 |
| , D.D.S | Pediatric Dentistry | New Haven, CT | $1,360 | 1 |
| , MD, MPH | Pediatric Emergency Medicine | Milwaukee, WI | $610.00 | 1 |
| , M.D | Pediatrics | San Diego, CA | $225.00 | 1 |
| , MD | Pediatric Allergy/Immunology | San Francisco, CA | $64.18 | 1 |
| , M.D | Pediatric Hematology-Oncology | San Francisco, CA | $64.18 | 1 |
Ad
Manufacturing Companies
- bluebird bio, Inc. $3.1M
Product Information
- Type Drug
- Total Payments $3.1M
- Total Doctors 22
- Transactions 90
About SKYSONA
SKYSONA is a drug associated with $3.1M in payments to 22 healthcare providers, recorded across 90 transactions in the CMS Open Payments database. The primary manufacturer is bluebird bio, Inc..
Payment data is available from 2023 to 2024. In 2024, $737,386 was paid across 28 transactions to 2 doctors.
The most common payment nature for SKYSONA is "Unspecified" ($2.9M, 94.2% of total).
SKYSONA is associated with 3 research studies, including "A Phase 3 Study of Lenti-D Drug Product After Myeloablative Conditioning Using Busulfan and Fludarabine in Subjects < 17 Years of Age With Cerebral Adrenoleukodystrophy (CALD)" ($2.1M).